Department of Neurology, The First Affiliated Hospital of Chongqing Medical University, Chongqing Key Laboratory of Neurology, Chongqing, China.
Center of Epilepsy, Beijing Institute for Brain Disorders, Beijing, China.
Front Immunol. 2018 Jun 8;9:1299. doi: 10.3389/fimmu.2018.01299. eCollection 2018.
Immunoglobulin has been widely used in a variety of diseases, including primary and secondary immunodeficiency diseases, neuromuscular diseases, and Kawasaki disease. Although a large number of clinical trials have demonstrated that immunoglobulin is effective and well tolerated, various adverse effects have been reported. The majority of these events, such as flushing, headache, malaise, fever, chills, fatigue and lethargy, are transient and mild. However, some rare side effects, including renal impairment, thrombosis, arrhythmia, aseptic meningitis, hemolytic anemia, and transfusion-related acute lung injury (TRALI), are serious. These adverse effects are associated with specific immunoglobulin preparations and individual differences. Performing an early assessment of risk factors, infusing at a slow rate, premedicating, and switching from intravenous immunoglobulin (IVIG) to subcutaneous immunoglobulin (SCIG) can minimize these adverse effects. Adverse effects are rarely disabling or fatal, treatment mainly involves supportive measures, and the majority of affected patients have a good prognosis.
免疫球蛋白已广泛应用于多种疾病,包括原发性和继发性免疫缺陷病、神经肌肉疾病和川崎病。虽然大量临床试验表明免疫球蛋白有效且耐受性良好,但也有报道称其存在各种不良反应。大多数这些事件,如潮红、头痛、不适、发热、寒战、疲劳和嗜睡,是短暂和轻微的。然而,一些罕见的副作用,包括肾功能损害、血栓形成、心律失常、无菌性脑膜炎、溶血性贫血和输血相关急性肺损伤(TRALI),是严重的。这些不良反应与特定的免疫球蛋白制剂和个体差异有关。早期评估危险因素、缓慢输注、预先用药以及从静脉注射免疫球蛋白(IVIG)转换为皮下免疫球蛋白(SCIG)可以最大程度地减少这些不良反应。不良反应很少导致残疾或致命,治疗主要包括支持措施,大多数受影响的患者预后良好。